CAJ | 학술논문

目的：通过荧光原位杂交（FISH）法检测胃癌Her-2基因扩增状况，评价曲妥珠单抗联合卡培他滨及奥沙利铂（Xelox方案）治疗晚期胃癌的效果。方法 FISH法检测32例晚期（IV期）胃癌患者Her-2基因均为扩增，按治疗方法不同分为两组：A组18例，采用曲妥珠单抗+Xelox方案治疗，B组14例，单用Xelox方案治疗。结果 A组疗效优于B组，差异有统计学意义（P＜0.05）。两组治疗后的不良反应均较轻，主要表现腹泻15例（49.2%），恶心、呕吐10例（32.1%），血白细胞下降27例（85.5%），手足综合征9例（29.6%），I度肝功能损害11例（33.9%）。无一例发生心脏毒性反应。结论曲妥珠单抗联合Xelox方案治疗Her-2阳性晚期胃癌是有效、安全可行的。
목적：통과형광원위잡교（FISH）법검측위암Her-2기인확증상황，평개곡타주단항연합잡배타빈급오사리박（Xelox방안）치료만기위암적효과。방법 FISH법검측32례만기（IV기）위암환자Her-2기인균위확증，안치료방법불동분위량조：A조18례，채용곡타주단항+Xelox방안치료，B조14례，단용Xelox방안치료。결과 A조료효우우B조，차이유통계학의의（P＜0.05）。량조치료후적불량반응균교경，주요표현복사15례（49.2%），악심、구토10례（32.1%），혈백세포하강27례（85.5%），수족종합정9례（29.6%），I도간공능손해11례（33.9%）。무일례발생심장독성반응。결론곡타주단항연합Xelox방안치료Her-2양성만기위암시유효、안전가행적。
Objective To evaluate the efficacy of transtuzumab combined with capecitabine and oxalipatin in treatment of gastric cancer. Methods Thirty two Her- 2 positive patients with advanced gastric cancer(stage IV), admitted from January 2010 to October 2012, were randomly assigned into two arms:18 patients in arm A received transtuzumab combined with capecitabine and oxalipatin (Xeolx), 14 patients in arm B receive Xeolx regime alone. Results Therapeutic efficacy of arm A was better than that of arm B(P<0.05). The adverse effects were gently in both groups,and mainly displayed I~II degree diarrhea(49.2%), nau-sea and vomiting (32.1%), bone marrow depression (85.5%), hand and foot syndrome (29.6%), and I degree liver function lesion (33.9%). No case developed heart toxic reaction. Conclusion Transtuzumab combined chemotherapy is effective and safe for Her- 2 positive patients with advanced gastric cancer.